TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Sponsor: Pierre Fabre Medicament · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT04913285 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04913285 Rescue Dossier →